BackgroundCheck.run
Search For

Steven K Macleod, 6822 Portofino Cir, Henrietta, NY 14467

Known as:
Steve K Macleod Steven K Malleod Steven K Macloud Steven Mccleod Steven Macleod Kelley Steve Mccleod
Related to:
Justin A Henry 33

Steven Macleod Phones & Addresses

22 Portofino Cir, Henrietta, NY 14467    585-3343492   

601 Montague Dr, Portage, MI 49024    269-3238893   

Kalamazoo, MI   

Rochester, NY   

North Plainfield, NJ   

North Brookfield, NY   

22 Portofino Cir, Henrietta, NY 14467    269-3238893   

Work

Position: Construction and Extraction Occupations

Education

Degree: High school graduate or higher
Get Report
Control this profile

Mentions for Steven K Macleod

Steven Macleod resumes & CV records

Resumes

Steven Macleod Photo 39

Senior Research Fellow And Group Leader

Location:
Webster, NY
Industry:
Medical Devices
Work:
Bausch + Lomb
Senior Research Fellow and Group Leader Pfizer Mar 2004 - Jan 2006
Research Fellow and Group Leader Pfizer Jan 2002 - Mar 2004
Senior Research Advisor and Fellow Pfizer 1992 - 1996
Senior Research Scientist and Group Leader Pfizer 1986 - 1992
Senior Research Scientist Union Carbide Oct 1983 - Sep 1986
Business Analytical Chemist
Education:
Colorado State University 1985 - 1985
Doctorates, Doctor of Philosophy, Chemistry Bates College 1978 - 1978
Bachelors, Bachelor of Science, Chemistry
Skills:
Analytical Chemistry, Validation, Pharmaceutical Industry, Hplc, Chemistry, Technology Transfer, Fda, Capa, Gmp, Quality Assurance, Glp, R&D, Drug Development, Drug Delivery, Clinical Development, Characterization, Lc Ms, Chromatography, Drug Discovery, Clinical Trials, Regulatory Affairs, Commercialization, Life Sciences, Product Development, Quality By Design, Piping, V&V, Cross Functional Team Leadership, Lifesciences, Team Building, Process Simulation, Hands on Technical Leadership, Root Cause Problem Solving
Interests:
Mechanochemistry
Plan B
Strategic Planning
Bagpiping
Steven Macleod Photo 40

Steven Macleod

Location:
United States
Steven Macleod Photo 41

Steven Macleod

Location:
United States

Publications & IP owners

Us Patents

Injectable Pharmaceutical Suspension In A Two-Chamber Vial

US Patent:
7387623, Jun 17, 2008
Filed:
Aug 20, 2003
Appl. No.:
10/644516
Inventors:
Steven K. MacLeod - Portage MI, US
Assignee:
Pfizer Inc. - New York NY
International Classification:
A61B 19/00
B65D 81/32
US Classification:
604416, 215 6, 206219
Abstract:
An article of manufacture is provided comprising a vial having (a) a first chamber that is substantially filled with an injectable pharmaceutical formulation; (b) a second chamber that is substantially empty but for a gaseous medium; (c) a septum, impermeable to the gaseous medium, separating the first and second chambers; and (d) actuating means effective to bring the formulation and the gaseous medium into contact by breach of the septum such that the gaseous medium acts as an effective headspace for agitation of the formulation. The formulation comprises an aqueous medium, a drug in solid particulate form in a therapeutically effective amount suspended in the medium, and one or more wetting and/or suspending agents in an amount effective to provide controlled flocculation of the drug, at least one ingredient of the formulation being susceptible to oxidative degradation.

Stabilized Injectable Suspension Of A Steroidal Drug

US Patent:
2003011, Jun 19, 2003
Filed:
Aug 21, 2002
Appl. No.:
10/225320
Inventors:
Steven MacLeod - Portage MI, US
Lloyd Fox - Richland MI, US
Neal Adams - Kalamazoo MI, US
David Salvat - Marcellus MI, US
International Classification:
A61K031/56
A61K031/57
A61K009/14
US Classification:
514/177000, 514/182000, 424/489000
Abstract:
A parenterally deliverable composition is provided, comprising an aqueous medium having dispersed therein, in solid particulate form, a steroidal drug in a therapeutically effective amount. The aqueous medium comprises one or more wetting and/or suspending agents in an amount effective to provide controlled flocculation of the drug, at least one of the wetting and/or suspending agents being susceptible to oxidative degradation. The composition further comprises, as a component thereof or as an adjunct thereto, means for protecting the oxidative degradation susceptible agent from oxidative degradation.

Ophthalmic Compositions Comprising A Carboxyl-Modified Fructan Or A Salt Thereof

US Patent:
2009003, Feb 5, 2009
Filed:
Jul 28, 2008
Appl. No.:
12/180694
Inventors:
Steven K. MacLeod - Henrietta NY, US
International Classification:
A61K 31/715
A61P 27/02
US Classification:
514 54
Abstract:
Ophthalmic composition including a carboxyl-modified fructan or a salt thereof. The ophthalmic composition can be used in an eye care product or a contact lens care product such as a contact lens packaging solution or contact lens disinfecting solution.

Ophthalmic Compositions With A Disuccinate

US Patent:
2009009, Apr 9, 2009
Filed:
Oct 7, 2008
Appl. No.:
12/246522
Inventors:
Steven K. MacLeod - Henrietta NY, US
International Classification:
A01N 37/52
A61K 31/195
A01P 1/00
US Classification:
424 7804, 514566, 514635
Abstract:
The invention is directed to an ophthalmic composition comprising a disuccinate of formula I or a corresponding salt thereof;wherein Ris selected from hydrogen, alkyl or —C(O)alkyl, the alkyl having one to twelve carbons and optionally one or more oxygen atoms, A is a methylene group or an oxyalkylene group, and n is from 2 to 8. The ophthalmic composition also includes a cationic antimicrobial component and a tonicity agent, wherein the tonicity agent provides for an osmolality of the composition from 200 mOs/kg to 420 mOsm/kg.

Pharmaceutical Formulations Comprising Stabilized Polysaccharides And Source Of Hydrogen Peroxide

US Patent:
2009030, Dec 10, 2009
Filed:
May 19, 2009
Appl. No.:
12/468136
Inventors:
Erning Xia - Penfield NY, US
Michael E. Allen - Webster NY, US
Steven K. MacLeod - Henrietta NY, US
Tammy J. Kleiber - Rochester NY, US
Graig M. Cody - Scottsville NY, US
International Classification:
A61K 33/40
A61K 33/22
C11D 3/04
US Classification:
424616, 424613, 510115
Abstract:
A pharmaceutical formulation that is effective in adversely affecting the viability of microorganisms or in inhibiting their growth and that provides better safety and/or comfort to the users comprises a polysaccharide, a source of hydrogen peroxide, and an anti-oxidant. The formulation can further comprise a chelating agent and/or an ophthalmically active agent for treating or controlling a disease or disorder of the eye. The formulation may be used to treat, clean, disinfect, store, wet, or rewet contact lenses.

Method For Preparing Suspensions Of Low-Solubility Materials

US Patent:
2010024, Sep 30, 2010
Filed:
Mar 1, 2010
Appl. No.:
12/714577
Inventors:
Steven K. MacLeod - Henrietta NY, US
Daniel J. Stein - Rochester NY, US
James Donald Hayes - Tampa FL, US
Donald L. Herber - Tampa FL, US
International Classification:
A61K 9/50
A61K 47/30
US Classification:
424501, 5147721
Abstract:
A process for producing a pharmaceutical suspension that comprises an active pharmaceutical ingredient (“API”) having low solubility, the process comprises: (a) preparing a first solution comprising a carboxy-containing vinyl polymer and a solvent; and (b) adding a compound of the API to said first solution under conditions of high-shear mixing for a time from about 5 minutes to about 5 hours, said compound being soluble in said solvent, thereby producing a suspension of particles of said API in a composition comprising said carboxy-containing vinyl polymer; wherein a concentration of said API in said suspension is higher than a solubility of said API in said solvent. The present invention also provides a suspension produced by such process.

Method For Preparing Suspensions Of Low-Solubility Materials

US Patent:
2015003, Feb 5, 2015
Filed:
Oct 21, 2014
Appl. No.:
14/519776
Inventors:
Steven K. MacLeod - Henrietta NY, US
Daniel J. Stein - Rochester NY, US
James Donald Hayes - Tampa FL, US
Donald L. Herber - Tampa FL, US
International Classification:
A61K 47/32
A61K 31/573
A61K 9/10
A61K 31/4709
A61K 31/196
A61K 9/14
A61K 31/55
A61K 31/7052
US Classification:
514 29, 51421711, 514180, 514300, 514567, 424489
Abstract:
A process for producing a pharmaceutical suspension that comprises an active pharmaceutical ingredient (“API”) having low solubility, the process comprises: (a) preparing a first solution comprising a carboxy-containing vinyl polymer and a solvent; and (b) adding a compound of the API to said first solution under conditions of high-shear mixing for a time from about 5 minutes to about 5 hours, said compound being soluble in said solvent, thereby producing a suspension of particles of said API in a composition comprising said carboxy-containing vinyl polymer; wherein a concentration of said API in said suspension is higher than a solubility of said API in said solvent. The present invention also provides a suspension produced by such process.

Possible Relatives

Dawn L Macleod  Dean H Macleod  Dale A Macleod  Daniel S Macleod  Aaron Macleod  Deidre R Macleod  Dennis K Macleod  Steven D Johnson  Steven B Standiford  Steven B Standley 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.